Phathom Pharmaceuticals (PHAT) Gross Margin (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Gross Margin data on file, last reported at 79.42% in Q1 2026.

• On a quarterly basis, Gross Margin fell 752.0% year-over-year to 79.42% in Q1 2026; TTM through Mar 2026 was 84.93%, a 130.0% decrease from a year earlier, with the FY2025 full-year figure at 87.09%, up 152.0% from the prior year.
• Gross Margin for Q1 2026 stood at 79.42%, down from 86.72% in the prior quarter.
• Over the last five years, Gross Margin for PHAT reached as high as 87.5% in Q3 2025 and fell as low as 75.51% in Q4 2023.
• Historically, Gross Margin has averaged 83.5% across 4 years, with a median of 86.16% in 2024.
• Across the five-year window, Gross Margin surged 1163 bps in 2024 and sank 752 bps in 2026, its largest moves.
• Year by year, Gross Margin stood at 75.51% in 2023, then rose by 15 bps to 87.14% in 2024, then decreased by 0 bps to 86.72% in 2025, then dropped by 8 bps to 79.42% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 79.42% in Q1 2026, 86.72% in Q4 2025, and 87.5% in Q3 2025.